Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis
Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis
We could not find results for this trial
What it found
We found no results in the registry or in papers.
This trial finished 4 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- biological collection
What it measured
Main measures
Description of cladribine's effects on immune system of multiple sclerosis patients
Through study completion, of 1 year
Who could take part
Relapsing and progressive · 18 to 65
Show the full criteria
Inclusion criteria
* Major Multiple Sclerosis (MS) Patients * RR MS patients without treatment (early stage disease) Or RR MS patients treated with first-line compounds (IFNβ, glatiramer acetate, teriflunomide and dimethyl fumarate, ...). Or RR MS patients treated with second-line compounds (natalizumab and fingolimod, ...) RR MS patients treated with third-line compounds (alemtuzumab, ...) Or Patients with progressive MS * Patients who have read and understood the information letter and signed the consent form * Person affiliated to a social security system
Exclusion criteria
* Patients under 18 years of age or over 65 years of age, * Patients who have benefited from immunosuppressive treatments for other autoimmune or cancerous pathologies, * Patients receiving treatments for multiple sclerosis and participating in phase 2, 3 or 4 protocols will be excluded. * Patients who have been treated for less than 1 year with cladribine, daclizumab, ocrelizumab, rituximab will be excluded. * Patients who have received mitoxantrone or a stem cell transplant, * Regulatory Criteria : * Person deprived of liberty by an administrative or judicial decision * Person placed under legal protection, sub-tutorship or curatorship
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The main objective of the project is therefore to study and thus better understand the immunomodulatory / anti-inflammatory effects of cladribine during multiple sclerosis. Most current and developing therapies targeting the immune system have no effect on the progressive phase of MS, during which neurodegeneration plays a predominant role. As mentioned above, the very promising results of clinical trials with cladribine tablets for the early and progressive phase of the disease have revealed immunomodulatory properties and suggested potential neuroprotective effects. It therefore plans to further dissect one of these two parameters by designing in vitro studies with peripheral blood mononuclear cells (PBMC) from healthy donors and MS patients.
Loading reviews and guidelines…
History
Started
Jul 2020
Main results due
Dec 2021
Finished
Dec 2021